Praxis precision medicines announces positive data from randomized withdrawal sub-study and long-term extension of essential1 study for ulixacaltamide

Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified activities of daily living 11 (madl11 1 )
PRAX Ratings Summary
PRAX Quant Ranking